A Retrospective Review of Malignant Liver Tumors
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will review the treatment and outcomes of patients having primary and metastatic hepatic malignancies. Patients treated with surgical resection, percutaneous radiofrequency ablation (RFA), and transarterial chemoembolization (TACE) will be compared with patients not receiving these treatments. Tumor recurrence and survival data will be compared to the published literature to determine the efficacy of current treatment strategies in this patient population.
| Condition |
|---|
|
Liver Cancer |
| Study Type: | Observational |
| Study Design: | Time Perspective: Retrospective |
| Official Title: | A Retrospective Review of Malignant Liver Tumors |
- Survival [ Time Frame: lifetime ] [ Designated as safety issue: No ]
- Efficacy [ Time Frame: lifetime ] [ Designated as safety issue: No ]
| Enrollment: | 228 |
| Study Start Date: | October 2003 |
| Study Completion Date: | June 2011 |
| Primary Completion Date: | October 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Observation
Patients with primary or metastatic hepatic malignancies
|
Detailed Description:
Subjects will be identified by diagnosis and procedure codes from a university surgical practice and the St. John Medical Center Cancer Registry. Data will be obtained by review of both the clinic and hospital charts. In addition we plan to review and utilize liver tumor treatment and outcomes data from a national database. Treatment decisions, in cases managed by the primary investigator, were made on a clinical basis, often in collaboration with an interventional radiologist. Of the patients managed by the principal investigator, all procedures were undertaken after an informed consent process. Subjects were not exposed to risk beyond that posed by the recommended treatment. All treatments were within the scope of standard medical care. The primary investigator has no knowledge of the treatments chosen for the patients he did not manage. The subject's referring physician may be contacted to obtain follow-up data on the subject. The follow-up data will include: is the patient alive with disease; alive without disease, alive unknown; dead free of disease; dead with disease; dead unknown.
Eligibility| Ages Eligible for Study: | 20 Years to 90 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Primary care clinic and patients treated at St. John Medical Center in Tulsa, OK
Inclusion Criteria:
- Patients with primary or metastatic hepatic malignancies
Exclusion Criteria:
- Patients not diagnosed with primary or metastatic hepatic malignancies
Contacts and Locations| United States, Oklahoma | |
| The University of Oklahoma College of Medicine, Tulsa - Department of Surgery | |
| Tulsa, Oklahoma, United States, 74135 | |
| Principal Investigator: | Thomas A Broughan, MD | University of Oklahoma-Tulsa |
More Information
Publications:
| Responsible Party: | University of Oklahoma |
| ClinicalTrials.gov Identifier: | NCT00728650 History of Changes |
| Other Study ID Numbers: | TAB11119 |
| Study First Received: | August 1, 2008 |
| Last Updated: | February 6, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Oklahoma:
|
hepatocellular carcinoma colorectal carcinoma metastatic to liver primary liver cancer |
Additional relevant MeSH terms:
|
Liver Neoplasms Digestive System Neoplasms Neoplasms by Site |
Neoplasms Digestive System Diseases Liver Diseases |
ClinicalTrials.gov processed this record on May 16, 2013